What's new? Log in Free sign up

Tiziana Life Sciences (TLSA)

Company Profile

Company profile

Ticker

TLSA

Exchange

Website

www.tizianalifesciences.com

CEO

Mr. Gabriele Marco Antonio Cerrone M.B.A.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

Tiziana Life Sciences plc

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Material Contracts & Credit Agreements

Subsidiaries Lists

TLSA stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab

Report of Foreign Private Issuer

Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Prospectus supplement for primary offering

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

Report of Foreign Private Issuer

Prospectus supplement for primary offering

Update and Interim Results for the Six Months Ended 30 June 2024

Latest ownership filings

Fonda Laura Natalia Monica

CERRONE GABRIEL M

Altium Capital Management LP

Empery Asset Management, LP

Altium Capital Management LP

Empery Asset Management, LP

Financial summary

Financial statements Chart TLSA financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q4 2021

TLSA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	24	EXIT
Opened positions	0	6	EXIT
Closed positions	24	5	+380.0%
Increased positions	0	7	EXIT
Reduced positions	0	5	EXIT

13F shares	Current	Prev Q	Change
Total value	0.00	2.04 mm	EXIT
Total shares	0.00	1.40 mm	EXIT
Total puts	0.00	0.00
Total calls	0.00	33.00 k	EXIT
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	0.00	-550.73 k	EXIT
STT State Street	0.00	-283.67 k	EXIT
MS Morgan Stanley	0.00	-179.46 k	EXIT
Geode Capital Management	0.00	-133.87 k	EXIT
BAC Bank of America	0.00	-50.31 k	EXIT
Ausdal Financial Partners	0.00	-46.90 k	EXIT
Marshall Wace	0.00	-41.46 k	EXIT
Capital Asset Advisory Services	0.00	-37.83 k	EXIT
Susquehanna International	0.00	-23.19 k	EXIT
Two Sigma Securities	0.00	-18.58 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Tiziana Life Sciences Broadens Phase 2 Clinical Trial For Non-Active Secondary Progressive Multiple Sclerosis To Additional U.S. Medical Institutions

The trial sites include esteemed institutions across the Northeast of the United States.Additional trial sites include:Yale UniversityJohns Hopkins UniversityCornell UniversityUniversity at Buffalo (SUNY)University of

Elon Musk Says Amazon Founder Jeff Bezos Urged Tesla, SpaceX Investors To Dump Stakes, Predicting Trump's Loss

Tesla Inc (NASDAQ: TLSA) and SpaceX, chief executive officer, Elon Musk sparked a new controversy by saying that Jeff Bezos, the founder and executive chairman of Amazon.com, predicted President-elect Donald Trump's defeat and asked people to sell stake in Musk's companies, before the election.

Cathie Wood Redirects Elon Musk's DOGE Focus Toward Nuclear Energy Amid Regulatory Challenges: Here's How Oklo, Cameco, Centrus Energy And Other Stocks Performed

Nuclear energy stocks and ETFs have come to the fore as ARK Invest's founder Cathie Wood reshared the firm's study on how regulatory hurdles and anti-nuclear sentiment have caused cost overruns and rendered nuclear energy less cost-competitive than natural gas today.

Tiziana Life Sciences To Participate In BIO-Europe 2024 To Discuss Recent Clinical Advancements, Including GLP-1 Combination Study Data

Reported Earlier, Tiziana Life Sciences Secures $5M in Direct Offering Of 5.3M Shares At $0.95/ Share for Immunotherapy Development

Press releases

From Benzinga Pro

Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development

Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.